Movatterモバイル変換

[0]ホーム
URL:

Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
Thehttps:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

NIH NLM Logo
Log inShow account info
Access keysNCBI HomepageMyNCBI HomepageMain ContentMain Navigation
pubmed logo
Advanced Clipboard
User Guide

Full text links

Public Library of Science full text link Public Library of Science Free PMC article
Full text links

Actions

Share

.2022 Mar 23;16(3):e0010287.
doi: 10.1371/journal.pntd.0010287. eCollection 2022 Mar.

Development of a dual antigen lateral flow immunoassay for detecting Yersinia pestis

Affiliations

Development of a dual antigen lateral flow immunoassay for detecting Yersinia pestis

Derrick Hau et al. PLoS Negl Trop Dis..

Abstract

Background: Yersinia pestis is the causative agent of plague, a zoonosis associated with small mammals. Plague is a severe disease, especially in the pneumonic and septicemic forms, where fatality rates approach 100% if left untreated. The bacterium is primarily transmitted via flea bite or through direct contact with an infected host. The 2017 plague outbreak in Madagascar resulted in more than 2,400 cases and was highlighted by an increased number of pneumonic infections. Standard diagnostics for plague include laboratory-based assays such as bacterial culture and serology, which are inadequate for administering immediate patient care for pneumonic and septicemic plague.

Principal findings: The goal of this study was to develop a sensitive rapid plague prototype that can detect all virulent strains of Y. pestis. Monoclonal antibodies (mAbs) were produced against two Y. pestis antigens, low-calcium response V (LcrV) and capsular fraction-1 (F1), and prototype lateral flow immunoassays (LFI) and enzyme-linked immunosorbent assays (ELISA) were constructed. The LFIs developed for the detection of LcrV and F1 had limits of detection (LOD) of roughly 1-2 ng/mL in surrogate clinical samples (antigens spiked into normal human sera). The optimized antigen-capture ELISAs produced LODs of 74 pg/mL for LcrV and 61 pg/mL for F1 when these antigens were spiked into buffer. A dual antigen LFI prototype comprised of two test lines was evaluated for the detection of both antigens in Y. pestis lysates. The dual format was also evaluated for specificity using a small panel of clinical near-neighbors and other Tier 1 bacterial Select Agents.

Conclusions: LcrV is expressed by all virulent Y. pestis strains, but homologs produced by other Yersinia species can confound assay specificity. F1 is specific to Y. pestis but is not expressed by all virulent strains. Utilizing highly reactive mAbs, a dual-antigen detection (multiplexed) LFI was developed to capitalize on the diagnostic strengths of each target.

PubMed Disclaimer

Conflict of interest statement

I have read the journal’s policy and the authors of this manuscript have the following competing interests: The goal of this research funded by Naval Research Laboratory contract ND0173-16-C-2003 and the Defense Threat Reduction Agency (DTRA) contract HDTRA1-16-C-0026 was to develop a diagnostic for plague. Currently the project is funded to transition these prototypes into an FDA approved diagnostic for plague through the MCDC contract # MCDC OTA W15QKN-16-9-1002.

Figures

Fig 1
Fig 1. Western blot analysis of anti-LcrV monoclonal antibodies (mAbs) againstYersinia pestis Harbin-35 lysate.
Horseradish peroxidase (HRP) conjugated LcrV mAbs (1 μg/mL) were used to probe(A) reduced and(B) non-reducedY.pestis Harbin-35 bacterial lysate (1.5x106 cells/lane) by direct Western blot.
Fig 2
Fig 2. Western blot analysis of anti-F1 monoclonal antibodies (mAbs) againstYersinia pestis Harbin-35 lysate.
Anti-F1 mAbs (1 μg/mL) were used to probe(A) reduced and(B) non-reducedY.pestis Harbin-35 bacterial lysate (1.5x106 cells/lane) by indirect Western blot. HRP-conjugated goat anti-mouse Ig was used for detection of F1 mAb binding.
Fig 3
Fig 3. Sensitivity ofY.pestis lateral flow immunoassays (LFI) using recombinant LcrV and F1.
LFI prototypes were tested with recombinant(A) LcrV and(B) F1 serial diluted into pooled normal human serum ranging from 0.25 to 256 ng/mL. Assay signal was evaluated and quantitated by optical density using a Qiagen ESE reader. Intensity ≥ 20 mm*mV scores as positive.
Fig 4
Fig 4. Specificity testing of dualYersinia pestis lateral flow immunoassay (LFI) against clinically relevant bacterial panel.
The dual LFI prototype containing test lines specific for LcrV (8F10/6F10) and F1 (11C7/3F2) was tested against a panel of bacterial lysates. Bacterial lysate (50 μL at OD600 = 0.5) was applied onto the conjugate pad and chased with buffer. LFIs were imaged after 20 minutes.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Benedictow O Jr. The Black Death, 1346–1353: the complete history. Woodbridge, Suffolk, UK; Rochester, N.Y., USA: Boydell Press; 2004. xvi, 433 pages p.
    1. Stenseth NC, Atshabar BB, Begon M, Belmain SR, Bertherat E, Carniel E, et al.. Plague: Past, Present, and Future. PLoS Med. 52008. - PMC - PubMed
    1. Lawrenz MB. Model Systems to Study Plague Pathogenesis and Develop New Therapeutics. Front Microbiol. 2010;1. doi: 10.3389/fmicb.2010.00119 ; PubMed Central PMCID: PMC3109633. - DOI - PMC - PubMed
    1. McCrumb FR Jr., Mercier S, Robic J, Bouillat M, Smadel JE, Woodward TE, et al.. Chloramphenicol and terramycin in the treatment of pneumonic plague. Am J Med. 1953;14(3):284–93. Epub 1953/03/01. doi: 10.1016/0002-9343(53)90040-0 . - DOI - PubMed
    1. Butler T. Plague Gives Surprises in the First Decade of the 21st Century in the United States and Worldwide. Am J Trop Med Hyg. 2013;89(4):788–93. doi: 10.4269/ajtmh.13-0191 ; PubMed Central PMCID: PMC3795114. - DOI - PMC - PubMed

Publication types

MeSH terms

Substances

Related information

Grants and funding

Funding from the Naval Research Laboratory contract ND0173-16-C-2003 (DA) supported the generation of mAbs and ELISA development. Funds from a Defense Threat Reduction Agency (DTRA) contract HDTRA1-16-C-0026 (DA) expanded the library of mAbs and allowed for the development and optimization of LFIs. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

LinkOut - more resources

Full text links
Public Library of Science full text link Public Library of Science Free PMC article
Cite
Send To

NCBI Literature Resources

MeSHPMCBookshelfDisclaimer

The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited.

[8]ページ先頭
©2009-2025 Movatter.jp